Clarity Pharmaceuticals Ltd CLRPF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.99
- Day Range
- $1.67–2.02
- 52-Week Range
- $1.23–3.60
- Bid/Ask
- $1.84 / $2.36
- Shares Outstanding
- 373.08M
- Market Cap
- $751.96M
- Volume/Avg
- 44,055 / 8,321
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
Valuation
|
Metric
|
CLRPF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.82 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CLRPF
|
|---|---|
Quick Ratio | 10.75 |
Current Ratio | 11.43 |
Interest Coverage | — |
Quick Ratio
CLRPF
Profitability
|
Metric
|
CLRPF
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CLRPF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|LcyVG! | LOCK|lm^$ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|jQWLy& | LOCK|&C@<$ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|Sb@@$% | LOCK|@dN | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|nQW@#<$$ | LOCK|rMVK> | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%QXLXJ | LOCK|&h | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qHMB&r | LOCK|F@lP | $29B | |||
| Incyte Corp
INCY
| LOCK|xLsPkV | LOCK|gy | $25B | |||
| Moderna Inc
MRNA
| LOCK|?Mwd^$ | LOCK|JP< | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|>xySlmC | LOCK|?@& | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|!M?^mk | LOCK|@^B | $17B |
United States